Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus

Inclusion Criteria: * patients eligible for a treatment by everolimus in association with the exemestane * Performance status of 0,1 or 2 according to the WHO * Patients affected of a breast cancer advanced and\\or metastatic HER2 negative expressing the hormonal receptor RH + * menopausal Patients Exclusion Criteria: * Psychiatric disease compromising the understanding of the information or the realization of the study * Vulnerable people according to the law (minors, adults under protection, private persons of freedom) * Histories of cancer in 5 years preceding the diagnosis (except breast cancer, squamous-cell) * Not menopausal women * Unaffiliated people to the Social Security * People being for the period of exclusion from another study * Hypersensitivity in the active substance, in the other by-products of the rapamycin or in one of the excipients. * Symptomatic visceral achievement * Legal incapacity or limited legal capacity